<?xml version="1.0" encoding="UTF-8"?>
<p>Mefloquine (MQ), a synthetic analog of quinine with a long history of use and good safety in humans, has been widely tested as an antiviral. One of the first reports refers to JCPyV. In 2009, Brickelmaier et al. chose MQ because of its high blood-brain barrier penetration capability since it accumulates in brain tissue at a six-fold higher concentration than its EC
 <sub>50</sub>. MQ was active against different strains of JCPyV in three different cell models, with EC
 <sub>50</sub>s within the low micromolar range [
 <xref rid="B71-microorganisms-08-00085" ref-type="bibr">71</xref>]. Because of the absence of a suitable animal model, this first paper represented the starting point for a series of trials in human populations, which obtained contrasting results and are summarized in 
 <xref rid="microorganisms-08-00085-t002" ref-type="table">Table 2</xref>. Seventeen case reports described the use of MQ at different doses [
 <xref rid="B72-microorganisms-08-00085" ref-type="bibr">72</xref>,
 <xref rid="B73-microorganisms-08-00085" ref-type="bibr">73</xref>,
 <xref rid="B74-microorganisms-08-00085" ref-type="bibr">74</xref>,
 <xref rid="B75-microorganisms-08-00085" ref-type="bibr">75</xref>,
 <xref rid="B76-microorganisms-08-00085" ref-type="bibr">76</xref>,
 <xref rid="B77-microorganisms-08-00085" ref-type="bibr">77</xref>,
 <xref rid="B78-microorganisms-08-00085" ref-type="bibr">78</xref>,
 <xref rid="B79-microorganisms-08-00085" ref-type="bibr">79</xref>,
 <xref rid="B80-microorganisms-08-00085" ref-type="bibr">80</xref>,
 <xref rid="B81-microorganisms-08-00085" ref-type="bibr">81</xref>,
 <xref rid="B82-microorganisms-08-00085" ref-type="bibr">82</xref>,
 <xref rid="B83-microorganisms-08-00085" ref-type="bibr">83</xref>,
 <xref rid="B84-microorganisms-08-00085" ref-type="bibr">84</xref>,
 <xref rid="B85-microorganisms-08-00085" ref-type="bibr">85</xref>,
 <xref rid="B86-microorganisms-08-00085" ref-type="bibr">86</xref>,
 <xref rid="B87-microorganisms-08-00085" ref-type="bibr">87</xref>,
 <xref rid="B88-microorganisms-08-00085" ref-type="bibr">88</xref>]. Although in 12 cases there was no progression of the disease at follow-up [
 <xref rid="B72-microorganisms-08-00085" ref-type="bibr">72</xref>,
 <xref rid="B73-microorganisms-08-00085" ref-type="bibr">73</xref>,
 <xref rid="B74-microorganisms-08-00085" ref-type="bibr">74</xref>,
 <xref rid="B77-microorganisms-08-00085" ref-type="bibr">77</xref>,
 <xref rid="B78-microorganisms-08-00085" ref-type="bibr">78</xref>,
 <xref rid="B79-microorganisms-08-00085" ref-type="bibr">79</xref>,
 <xref rid="B81-microorganisms-08-00085" ref-type="bibr">81</xref>,
 <xref rid="B82-microorganisms-08-00085" ref-type="bibr">82</xref>,
 <xref rid="B83-microorganisms-08-00085" ref-type="bibr">83</xref>,
 <xref rid="B84-microorganisms-08-00085" ref-type="bibr">84</xref>,
 <xref rid="B86-microorganisms-08-00085" ref-type="bibr">86</xref>,
 <xref rid="B87-microorganisms-08-00085" ref-type="bibr">87</xref>], it is difficult to draw conclusions due to the challenging treatment protocols and compromised health of the patients. In many cases, MQ was combined with mirtazapine, an antidepressant that, acting on the 5-HT2A serotonin receptor, is able to inhibit JCPyV entry into glial cells, preventing the diffusion of the infection in oligodendrocytes. The outcomes of this treatment are controversial, leading to the resolution of the infection, with a claimed effect of MQ and mirtazapine treatment [
 <xref rid="B86-microorganisms-08-00085" ref-type="bibr">86</xref>,
 <xref rid="B87-microorganisms-08-00085" ref-type="bibr">87</xref>,
 <xref rid="B89-microorganisms-08-00085" ref-type="bibr">89</xref>,
 <xref rid="B90-microorganisms-08-00085" ref-type="bibr">90</xref>,
 <xref rid="B91-microorganisms-08-00085" ref-type="bibr">91</xref>,
 <xref rid="B92-microorganisms-08-00085" ref-type="bibr">92</xref>,
 <xref rid="B93-microorganisms-08-00085" ref-type="bibr">93</xref>,
 <xref rid="B94-microorganisms-08-00085" ref-type="bibr">94</xref>,
 <xref rid="B95-microorganisms-08-00085" ref-type="bibr">95</xref>,
 <xref rid="B96-microorganisms-08-00085" ref-type="bibr">96</xref>,
 <xref rid="B97-microorganisms-08-00085" ref-type="bibr">97</xref>,
 <xref rid="B98-microorganisms-08-00085" ref-type="bibr">98</xref>,
 <xref rid="B99-microorganisms-08-00085" ref-type="bibr">99</xref>,
 <xref rid="B100-microorganisms-08-00085" ref-type="bibr">100</xref>,
 <xref rid="B101-microorganisms-08-00085" ref-type="bibr">101</xref>,
 <xref rid="B102-microorganisms-08-00085" ref-type="bibr">102</xref>,
 <xref rid="B103-microorganisms-08-00085" ref-type="bibr">103</xref>,
 <xref rid="B104-microorganisms-08-00085" ref-type="bibr">104</xref>,
 <xref rid="B105-microorganisms-08-00085" ref-type="bibr">105</xref>], and to the resolution of the infection probably due to other factors [
 <xref rid="B96-microorganisms-08-00085" ref-type="bibr">96</xref>,
 <xref rid="B106-microorganisms-08-00085" ref-type="bibr">106</xref>,
 <xref rid="B107-microorganisms-08-00085" ref-type="bibr">107</xref>,
 <xref rid="B108-microorganisms-08-00085" ref-type="bibr">108</xref>,
 <xref rid="B109-microorganisms-08-00085" ref-type="bibr">109</xref>] or to the death of the patient, which was not always directly related to the unsuccessful therapy [
 <xref rid="B87-microorganisms-08-00085" ref-type="bibr">87</xref>,
 <xref rid="B96-microorganisms-08-00085" ref-type="bibr">96</xref>,
 <xref rid="B110-microorganisms-08-00085" ref-type="bibr">110</xref>,
 <xref rid="B111-microorganisms-08-00085" ref-type="bibr">111</xref>,
 <xref rid="B112-microorganisms-08-00085" ref-type="bibr">112</xref>,
 <xref rid="B113-microorganisms-08-00085" ref-type="bibr">113</xref>,
 <xref rid="B114-microorganisms-08-00085" ref-type="bibr">114</xref>,
 <xref rid="B115-microorganisms-08-00085" ref-type="bibr">115</xref>,
 <xref rid="B116-microorganisms-08-00085" ref-type="bibr">116</xref>]. In one case, the suspension of the therapy was necessary due to the side effects [
 <xref rid="B117-microorganisms-08-00085" ref-type="bibr">117</xref>]. In a few cases, a third partner drug was added to MQ and mirtazapine. Again, the outcome was variable, and the contribution of the single drugs was difficult to determine [
 <xref rid="B118-microorganisms-08-00085" ref-type="bibr">118</xref>,
 <xref rid="B119-microorganisms-08-00085" ref-type="bibr">119</xref>].
</p>
